The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis-Reference-Cited by-同舟云学术

The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis

Published:2023-10-31 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Huang Xiaohua¹^ORCID,Liu Yuan²,Liu Ruixuan²,Zou Xiaoqiu³,Yang Hongyong¹

Affiliation:

1. Department of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, People’s Republic of China

2. The First Clinical Medicine College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, People’s Republic of China

3. Department of Traditional Chinese Medicine, Guangzhou Liwan Maternal and Child Health Hospital, Guangzhou, People’s Republic of China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2274149

Reference62 articles.

1. Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

2. Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study

3. Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes

4. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

5. Primary Myelodysplastic Syndromes

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1;Leukemia Research;2024-09